BE2015C053I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2015C053I2 BE2015C053I2 BE2015C053C BE2015C053C BE2015C053I2 BE 2015C053 I2 BE2015C053 I2 BE 2015C053I2 BE 2015C053 C BE2015C053 C BE 2015C053C BE 2015C053 C BE2015C053 C BE 2015C053C BE 2015C053 I2 BE2015C053 I2 BE 2015C053I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49977103P | 2003-09-03 | 2003-09-03 | |
EP03103275 | 2003-09-03 | ||
EP03103319 | 2003-09-08 | ||
EP03103335 | 2003-09-10 | ||
EP03103668 | 2003-10-02 | ||
US50848603P | 2003-10-03 | 2003-10-03 | |
EP04787096.9A EP1663240B2 (fr) | 2003-09-03 | 2004-09-03 | Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti) |
PCT/EP2004/052028 WO2005021001A1 (fr) | 2003-09-03 | 2004-09-03 | Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2015C053I2 true BE2015C053I2 (fr) | 2023-12-14 |
Family
ID=34280181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2015C053C BE2015C053I2 (fr) | 2003-09-03 | 2015-10-21 |
Country Status (25)
Country | Link |
---|---|
US (9) | US20080200435A1 (fr) |
EP (1) | EP1663240B2 (fr) |
JP (3) | JP5507791B2 (fr) |
KR (1) | KR20060090658A (fr) |
CN (1) | CN101060844B (fr) |
AP (1) | AP2109A (fr) |
AU (5) | AU2004268390B2 (fr) |
BE (1) | BE2015C053I2 (fr) |
CA (1) | CA2537095C (fr) |
CY (5) | CY2015038I2 (fr) |
FI (1) | FI1663240T4 (fr) |
FR (3) | FR15C0072I2 (fr) |
HK (1) | HK1092698A1 (fr) |
HR (1) | HRP20150798T4 (fr) |
HU (5) | HUS1500052I1 (fr) |
IL (2) | IL173438A (fr) |
LT (2) | LTC1663240I2 (fr) |
LU (3) | LU92853I2 (fr) |
MX (1) | MXPA06002437A (fr) |
MY (1) | MY169670A (fr) |
NL (2) | NL300781I2 (fr) |
NO (5) | NO334877B1 (fr) |
NZ (1) | NZ545306A (fr) |
PL (1) | PL1663240T5 (fr) |
WO (1) | WO2005021001A1 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
CN100554245C (zh) | 2002-08-09 | 2009-10-28 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
CN105596356A (zh) | 2003-01-14 | 2016-05-25 | 吉里德科学公司 | 用于联合抗病毒治疗的组合物和方法 |
UA92467C2 (ru) * | 2004-09-02 | 2010-11-10 | Янссен Фармацевтика Н.В. | Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила |
SI1789139T1 (sl) * | 2004-09-02 | 2012-08-31 | Janssen Pharmaceutica Nv | Fumarat 4-((4-((4-(2-cianoetenil)-2,6-dimetifenil amino-2-pirimidinil amino benzonitrila |
PT1632232E (pt) * | 2004-09-02 | 2011-08-02 | Janssen Pharmaceutica Nv | Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo |
AU2005279158C1 (en) * | 2004-09-02 | 2010-12-16 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
WO2006024667A1 (fr) * | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Furamate de 4- ( (4- ( (4- (2-cyanoethenyl) -2, 6-dimethylphenyl) amino) -2-pyrimidinyl) amino) benzonitrile |
TWI457136B (zh) * | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
KR20080091767A (ko) * | 2005-12-14 | 2008-10-14 | 씨아이피엘에이 엘티디. | (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물 |
AP2936A (en) * | 2006-01-20 | 2014-07-31 | Tibotec Pharm Ltd | Long term treatment of HIV-infection with TMC278 |
US9044509B2 (en) | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
CL2008000746A1 (es) * | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
DK2234620T3 (en) | 2008-01-03 | 2016-06-06 | Université D'aix-Marseille | Triple therapy used for treatment of an hiv-infected patient |
WO2010072844A1 (fr) * | 2008-12-24 | 2010-07-01 | Tibotec Pharmaceuticals | Dispositifs implantables pour le traitement du vih |
JP5950825B2 (ja) | 2009-12-21 | 2016-07-13 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 活性化合物の持続放出のための分解性の取り外し可能なインプラント |
UA105556C2 (uk) | 2010-01-27 | 2014-05-26 | Віів Гелскер Компані | Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами |
BR112013012245B1 (pt) * | 2010-11-19 | 2022-09-27 | Janssen Sciences Ireland Uc | Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv |
WO2012125993A1 (fr) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Formes à l'état solide de base rilpivirine et sels de rilpivirine |
EP2755959B1 (fr) * | 2011-09-16 | 2018-05-16 | Hetero Research Foundation | Chlorhydrate de rilpivirine |
NZ718708A (en) | 2012-12-21 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR102606625B1 (ko) | 2015-11-09 | 2023-11-27 | 길리애드 사이언시즈, 인코포레이티드 | 인간 면역결핍 바이러스의 치료를 위한 치료 조성물 |
JP7197474B2 (ja) | 2016-10-24 | 2022-12-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 分散性組成物 |
WO2018119371A1 (fr) * | 2016-12-23 | 2018-06-28 | Temple University - Of The Commonwealth System Of Higher Education | Activité anti-flaviviridae d'inhibiteurs de la transcriptase inverse nucléosidiques et non nucléosidiques anti-rétroviraux (nnrtis) |
CA3060222A1 (fr) * | 2017-04-18 | 2018-10-25 | Cipla Limited | Polytherapie destinee a etre utilisee dans le traitement d'infections retrovirales |
WO2019021319A1 (fr) * | 2017-07-27 | 2019-01-31 | Cipla Limited | Compositions pharmaceutiques |
KR20220109389A (ko) | 2019-11-29 | 2022-08-04 | 스키피오 라이프 사이언스 리미티드 | 릴피비린을 포함하는 조성물 및 종양 또는 암 치료를 위한 이의 용도 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182111A (en) | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US5368864A (en) | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
DK0489181T3 (da) | 1990-07-19 | 1996-11-18 | Otsuka Pharma Co Ltd | Fast præparat |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
CA2121129A1 (fr) | 1991-10-29 | 1993-05-13 | Patrick Soon-Shiong | Polysaccharides pouvant etre reticules, polycations et lipides, utiles pour l'encapsulation et la liberation controlee de medicaments |
AU4079593A (en) | 1992-05-13 | 1993-12-13 | Wellcome Foundation Limited, The | Therapeutic combinations |
JPH06316524A (ja) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | 抗エイズウイルス剤 |
TW401303B (en) * | 1994-07-01 | 2000-08-11 | Janssen Pharmaceutica Nv | Anti-HIV triple combination |
IT1281502B1 (it) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
KR100801588B1 (ko) | 1999-09-21 | 2008-02-05 | 스키에파마 캐나다 인코포레이티드 | 생물학적 유효 물질의 표면 변형된 미립자 조성물 |
US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
TW200800298A (en) | 2000-01-27 | 2008-01-01 | Zentaris Ag | Compressed microparticles for dry injection |
US7135465B2 (en) | 2000-03-30 | 2006-11-14 | Bristol-Myers Squibb Company | Sustained release beadlets containing stavudine |
US20040115268A1 (en) | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
DE10050199A1 (de) | 2000-10-11 | 2002-04-25 | Ethicon Gmbh | Flächiges Implantat mit im Ultraschall detektierbaren Elementen |
CA2431319A1 (fr) | 2000-12-11 | 2002-06-20 | Hiroto Bando | Composition medicinale dont la solubilite dans l'eau est amelioree |
ES2333645T3 (es) | 2001-06-22 | 2010-02-25 | Bend Research, Inc. | Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros. |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US20030166509A1 (en) | 2001-11-20 | 2003-09-04 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery and methods of use thereof |
CN100554245C (zh) | 2002-08-09 | 2009-10-28 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
AU2003278766A1 (en) | 2002-09-04 | 2004-03-29 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
AU2003291457A1 (en) | 2002-11-08 | 2004-06-03 | Glaxo Group Limited | Pharmaceutical antiviral compositions |
AP1927A (en) | 2002-11-15 | 2008-12-10 | Tibotec Pharm Ltd | Substituted indolepyridinium as anti-infective compounds |
WO2004050068A1 (fr) | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Compositions pharmaceutiques comprenant un compose medicamenteux respectivement basique, tensioactif et base respectivement acide hydrosoluble et tolerable physiologiquement |
JP5602333B2 (ja) | 2003-02-07 | 2014-10-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Hiv感染の予防のためのピリミジン誘導体 |
KR100629771B1 (ko) | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
RU2373923C2 (ru) | 2004-06-08 | 2009-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
PT1632232E (pt) | 2004-09-02 | 2011-08-02 | Janssen Pharmaceutica Nv | Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo |
AU2005279158C1 (en) | 2004-09-02 | 2010-12-16 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
EP2623095A1 (fr) | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Formulations injectables de nanoparticules d'olanzapine |
TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
AR056652A1 (es) | 2005-04-11 | 2007-10-17 | Tibotec Pharm Ltd | Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento |
WO2006110889A2 (fr) | 2005-04-11 | 2006-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Structure multicouche possedant une configuration predeterminee comprenant un agent |
US20090142401A1 (en) | 2005-06-07 | 2009-06-04 | Leah Elizabeth Appel | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release |
JP5243247B2 (ja) | 2005-07-28 | 2013-07-24 | アイエスピー インヴェストメンツ インコーポレイテッド | スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品 |
AP2936A (en) | 2006-01-20 | 2014-07-31 | Tibotec Pharm Ltd | Long term treatment of HIV-infection with TMC278 |
PL2040671T3 (pl) | 2006-06-23 | 2018-08-31 | Janssen Sciences Ireland Uc | Wodne zawiesiny TMC278 |
WO2008060360A2 (fr) | 2006-09-28 | 2008-05-22 | Surmodics, Inc. | Dispositif médical implantable pourvu d'ouvertures pour administrer des agents bioactifs |
CL2008000746A1 (es) | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
AU2008274185B2 (en) | 2007-07-12 | 2014-07-03 | Janssen Sciences Ireland Uc | Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
WO2009046299A2 (fr) | 2007-10-04 | 2009-04-09 | Boston Scientific Scimed, Inc | Forme retard implantable pour un système antidouleur d'administration de médicament intrarachidien |
WO2010047819A1 (fr) | 2008-10-24 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Dérivés d'hydroxyéthylaminosulfonamide |
-
2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en active Active
- 2004-09-03 CA CA2537095A patent/CA2537095C/fr active Active
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/fr active Active
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh active Active
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en unknown
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/fr active Application Filing
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja active Active
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko active Search and Examination
-
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
- 2006-12-05 HK HK06113340.4A patent/HK1092698A1/xx active IP Right Maintenance
-
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en active Active
-
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en active Active
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
-
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja active Active
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
-
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 NL NL300781C patent/NL300781I2/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/fr unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/fr unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 CY CY2015038C patent/CY2015038I2/el unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I1/el unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/fr unknown
-
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I2/el unknown
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 CY CY2016049C patent/CY2016049I1/el unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
-
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
-
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
-
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned